公开(公告)号：US20250135006A1

公开(公告)日：2025-05-01

申请号：US18763016

申请日：2024-07-03

Applicant: Pfizer Inc.

Inventor： Derek William Bartlett ,  Zoltan Beck ,  Andrew Fensome ,  Mark Edward Flanagan ,  Michael William Pride

IPC: A61K47/22 ,  A61K31/496 ,  A61K39/39 ,  A61K47/28

Abstract: The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, L, X, Y and p are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may modulate the activity of antigens of interest and may be useful in inducing or enhancing an immune response against diseases, disorders and conditions mediated by antigens of interest.

公开(公告)号：US12077533B2

公开(公告)日：2024-09-03

申请号：US17393463

申请日：2021-08-04

Applicant: Pfizer Inc.

Inventor： Atli Thorarensen ,  Matthew Frank Brown ,  Agustin Casimiro-Garcia ,  Ye Che ,  Jotham Wadsworth Coe ,  Mark Edward Flanagan ,  Adam Matthew Gilbert ,  Matthew Merrill Hayward ,  Jonathan David Langille ,  Justin Ian Montgomery ,  Jean-Baptiste Telliez ,  Rayomand Jal Unwalla ,  John I Trujillo

IPC: A61K31/4523 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04

CPC classification number: C07D471/04 ,  A61K31/4523 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04

Abstract: The present invention provides a method for treating alopecia using certain pharmaceutically active pyrrolo[2,3-d]pyrimidinyl acrylamides having the structure:




or a pharmaceutically acceptable salt thereof, as set forth in the Description.

公开(公告)号：US11111242B2

公开(公告)日：2021-09-07

申请号：US15446500

申请日：2017-03-01

Applicant: Pfizer Inc.

Inventor： Atli Thorarensen ,  Matthew Frank Brown ,  Agustin Casimiro-Garcia ,  Ye Che ,  Jotham Wadsworth Coe ,  Mark Edward Flanagan ,  Adam Matthew Gilbert ,  Matthew Merrill Hayward ,  Jonathan David Langille ,  Justin Ian Montgomery ,  Jean-Baptiste Telliez ,  Rayomand Jal Unwalla ,  John I. Trujillo

IPC: A61K31/4523 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04

Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylam ides and analogues thereof, having the structure: or a pharmaceutically acceptable salt thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

公开(公告)号：US09545405B2

公开(公告)日：2017-01-17

申请号：US14691606

申请日：2015-04-21

Applicant: Pfizer Inc.

Inventor： Matthew Frank Brown ,  Ashley Edward Fenwick ,  Mark Edward Flanagan ,  Andrea Gonzales ,  Timothy Allan Johnson ,  Neelu Kaila ,  Mark J. Mitton-Fry ,  Joseph Walter Strohbach ,  Ruth E. TenBrink ,  John David Trzupek ,  Rayomand Jal Unwalla ,  Michael L. Vazquez ,  Mihir D. Parikh

IPC: A01N43/90 ,  A61K31/519 ,  C07D487/00 ,  C07D487/04 ,  C07D519/00 ,  A61K31/5386 ,  C07D207/18

CPC classification number: A61K31/519 ,  A61K31/5386 ,  C07D207/18 ,  C07D487/04 ,  C07D519/00

Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.

公开(公告)号：US20150246048A1

公开(公告)日：2015-09-03

申请号：US14715046

申请日：2015-05-18

Applicant: Pfizer Inc.

Inventor： Matthew Frank Brown ,  Ashley Edward Fenwick ,  Mark Edward Flanagan ,  Andrea Gonzales ,  Timothy Allan Johnson ,  Neelu Kaila ,  Mark J. Mitton-Fry ,  Joseph Walter Strohbach ,  Ruth E. TenBrink ,  John David Trzupek ,  Rayomand Jal Unwalla ,  Michael L. Vazquez ,  Mihir D. Parikh

IPC: A61K31/519 ,  A61K31/5386

CPC classification number: A61K31/519 ,  A61K31/5386 ,  C07D207/18 ,  C07D487/04 ,  C07D519/00

Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.

Abstract translation: 本文描述的是吡咯并[2,3-d]嘧啶衍生物，它们用作Janus Kinase（JAK）抑制剂，以及含有它们的药物组合物。